MedTrace Logo

Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)

NCT02425592 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 223

Last updated 2025-07-23

No results posted yet for this study

Summary

The objective in this study is to determine if MRI-identified progression can decrease frequency or need for repeated prostate biopsy in men on active surveillance (AS).

Our hypothesis is that MRI alone is adequate to detect progression of prostate cancer in men on active surveillance (AS) after a MRI-US fusion prostate biopsy.

Conditions

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Preston Sprenkle, MD · Yale University

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2022-05-30
Completion
2025-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02425592 on ClinicalTrials.gov